GDC-0077 CAS No.:2060571-02-8

Introducing GDC-0077 CAS No.:2060571-02-8 - A Revolutionary Product for Cutting-Edge Applications

As a manufacturer based in China, we are excited to offer our latest innovation to merchants worldwide - GDC-0077. This incredible new product is a game-changer in numerous industries, from pharmaceuticals to materials science, with its wide range of applications and unmatched benefits.

So, what exactly is GDC-0077? Let's dive in and explore its major features, applications, and advantages, and how you can leverage them for your business.

GDC-0077 - A Brief Overview

GDC-0077 is a small molecule inhibitor that selectively targets a key oncogenic signaling pathway called PI3Kα. It is a potent compound that has shown excellent efficacy against various cancers, including breast, lung, colon, and pancreatic cancers, as well as solid tumor types, such as glioblastoma, prostate, and ovarian cancers.

Additionally, GDC-0077 exhibits superior selectivity, pharmacokinetics, and safety profiles than other PI3Kα inhibitors, making it an ideal choice for cancer therapy. The compound is also structurally unique, with a thieno[3,2-d]pyrimidine-based core that interacts with the key residues in the PI3Kα binding site. Such unique features provide GDC-0077 with the necessary potency and specificity required for precise cancer therapy.

Major Applications of GDC-0077

As mentioned earlier, GDC-0077 has broad applications in different fields, which are summarized below:

1. Oncology

GDC-0077 has emerged as a promising candidate for cancer treatment, with encouraging preclinical and clinical data. It acts as an inhibitor of the PI3K/AKT/mTOR pathway, a critical regulator of cell proliferation, invasion, and survival. Inhibiting this pathway can trigger apoptosis (programmed cell death), reduce tumor growth, and increase drug sensitivity.

Several ongoing Phase 1 and 2 clinical trials have demonstrated that GDC-0077 exhibits excellent efficacy and tolerability, both as a standalone treatment and in combination with other anticancer agents. For instance, a Phase 1 study in Japan showed that GDC-0077 has a favorable pharmacokinetic profile, with a good safety margin and a well-tolerated dose range. Another Phase 1 study in the US revealed that GDC-0077 has significant therapeutic benefits for advanced solid tumors, including breast, ovarian, and endometrial cancers.

2. Materials Science

GDC-0077 has shown some intriguing properties that make it useful for the development of several materials. The compound can act as an efficient corrosion inhibitor for metal surfaces, protecting them against oxidation and rusting. It can also enhance the thermal stability and mechanical properties of polymers when used in small amounts. Such benefits make GDC-0077 a practical solution for the manufacturing of various industrial and consumer products.

3. Agriculture

GDC-0077 also has potential applications in the agricultural sector. Studies have shown that GDC-0077 can promote plant growth, increase yield, and alleviate stress under adverse environmental conditions, such as drought, salinity, and oxidative stress. The compound can also improve the quality and nutrient content of crops, making it an attractive tool for sustainable agriculture.

Advantages of GDC-0077

1. Selectivity

GDC-0077 is highly selective in inhibiting PI3Kα, which means it has minimal off-target effects on other cellular proteins. Such selectivity ensures that the compound acts precisely on the target cells and avoids damaging healthy cells, reducing potential side effects.

2. Potency

GDC-0077 is a potent compound, with a lower IC50 value than other PI3Kα inhibitors. As a result, it requires lower doses and shorter treatment time to achieve the desired therapeutic benefits.

3. Safety

GDC-0077 has a well-tolerated safety profile, with no significant adverse events reported in clinical trials. The compound also shows low toxicity and minimal drug-drug interactions, making it safe for patients with pre-existing conditions or taking other medications.

4. Cost-effective

GDC-0077 is cost-effective compared to other PI3Kα inhibitors and other cancer therapies. It requires a lower dose, shorter treatment duration, and fewer doses than other agents, reducing treatment costs significantly.

Conclusion

GDC-0077 is a groundbreaking product that offers solutions to various challenges in oncology, materials science and agriculture. Its unique features, including selectivity, potency, safety and cost-effectiveness, make it an attractive solution for different industries. As a manufacturer, we are confident that GDC-0077 can add value to your business and help you achieve your goals. Don't hesitate to contact us for further information or to place your order today.

Chemical Structure : Inavolisib

CAS No.: 2060571-02-8

 

Inavolisib(GDC-0077;RG-6114)

Catalog No.: URK-V1085 Only Used For Lab.

GDC-0077 (Inavolisib, RG-6114) is a potent, highly isoform selective inhibitor of PI3Kα, with IC50 of 0.038 nM.

Biological Activity

GDC-0077 (Inavolisib, RG-6114) is a potent, highly isoform selective inhibitor of PI3Kα, with IC50 of 0.038 nM.
GDC-0077 displays >300-fold selective over β, δ, and γ isoforms, as well as PIKK-family proteins such as mTOR, DNA-PK and VPS34.
GDC-0077 induces depletion of mutant PI3K alpha protein resulting in reduction of PI3K pathway biomarkers such as pAkt and pPRAS40, inhibition of cell proliferation and increased apoptosis in human PIK3CA mutant breast cancer cell lines to a greater extent when compared to PIK3CA wild-type cells.
GDC-0077 causes tumor regressions in cell-culture-derived and patient derived PIK3CA mutant breast cancer xenograft models.

Physicochemical Properties

References

1. Kyle Edgar, et al. Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development. AACR July 2017.

URK-V1085_COA

URK-V1085_SDS

URK-V1085_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We are committed to manufacturing high-quality PI3K/Akt/mTOR Pathway Library products that are both durable and reliable.
• Satisfying the requirements of customers is our basic task, and the needs of customers are our happiness.
• We offer flexible and affordable pricing options for our PI3K/Akt/mTOR Pathway Library products and services.
• Our company's goal is to develop new markets or regions and accelerate the launch of new GDC-0077 CAS No.:2060571-02-8 or services.
• At our factory, we are passionate about providing the best possible PI3K/Akt/mTOR Pathway Library products and services.
• We stick to the spirit of craftsmanship to the end, reflecting the love and dedication of each of our employees in every job.
• We offer superior PI3K/Akt/mTOR Pathway Library products and services with unparalleled customer support.
• We believe that there is contact, there is understanding, as long as there is understanding, we will be your partner and friend.
• Our PI3K/Akt/mTOR Pathway Library products are manufactured with the highest quality materials and care.
• We continue to provide efficient and high-end services and unique and constantly innovative GDC-0077 CAS No.:2060571-02-8 to our customers with our high-quality whole process service concept.

Hot Tags: gdc-0077 cas no.:2060571-02-8, China gdc-0077 cas no.:2060571-02-8, agonists for drug metabolism, agonists for cell proliferation, epigenetic library for epigenetic attenuation, agonists for immune system modulation, inhibitors for apoptosis regulation, epigenetic library for epigenetic regulation of cell apoptosis